Healthcare / Drug Manufacturers - Specialty & GenericTaipei ExchangeTW
$34.60
+0.25 (+0.73%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $75.9M · quality 47.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.4B
P/E
49.4x
↑EV/EBITDA
12.8x
↑ROE
3.5%
↑Gross Margin
28.2%
↓Debt/Equity
0.40
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.2%
FCF CAGR
—
FCF margin
11.2%
FCF / Net income
2.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $677.1M · net income $28.9M · FCF $75.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $677.1M | $677.1M | $521.2M | $793.8M | $634.0M |
| Net Income | $28.9M | $28.9M | $-22.5M | $124.6M | $93.5M |
| EBITDA | $115.4M | $115.4M | $56.3M | $231.1M | $164.1M |
| EPS | — | — | -0.54 | 2.99 | 2.20 |
| Gross Margin | 28.2% | 28.2% | 18.6% | 36.1% | 35.0% |
| Operating Margin | 6.8% | 6.8% | -6.8% | 19.3% | 16.0% |
| Net Margin | 4.3% | 4.3% | -4.3% | 15.7% | 14.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.40 | 0.40 | 0.31 | 0.17 | 0.26 |
| Current Ratio | 3.25 | 3.25 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $75.9M | $75.9M | $-14.6M | $118.9M | $-156.0M |
| Returns | |||||
| ROE | 3.5% | 3.5% | -2.9% | 14.0% | 11.2% |
| Valuation | |||||
| P/E | 49.43 | 49.43 | — | 24.65 | 30.45 |
| EV/EBITDA | 12.81 | 12.81 | 36.49 | 13.41 | 18.11 |
| P/B | 1.76 | 1.76 | 2.45 | 3.43 | 3.43 |
| Growth & Yield | |||||
| Revenue Growth | 29.9% | 29.9% | -34.3% | 25.2% | — |
| EPS Growth | — | — | -118.1% | 35.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.54 → n/d
Residual
-23.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.